| INTRODUCTION
Interleukin-36 (IL-36) cytokines are part of the wider IL-1 family and include IL-36α, IL-36β, IL-36γ and their inhibitor, the IL-36 receptor antagonist (IL-36Ra).
[1] IL-36 binds to the IL-36 receptor (IL-36R) and this is followed by recruitment of an accessory protein (IL-RAcP), which is shared by other IL-1 members. [2] Downstream intra-cellular signalling results in NF-κB and AP-1 activation and the expression of proinflammatory mediators in susceptible cells.
Whilst the receptor antagonist is able to bind to the receptor, it does not recruit the AcP receptor, so signalling does not occur, and thus, the Ra exerts antagonist effects. [3, 4] IL-36γ is thought to be mainly produced by keratinocytes and other epithelial cells in response to stimuli such as fungi, inflammatory mediators such as TNF-α and IL-1, bacteria, rhinovirus infection and smoke. [5] [6] [7] [8] [9] IL-36
has stimulatory effects on a range of cell types including epithelial cells, fibroblasts and immune cells. [6, [10] [11] [12] IL-36 expressed by epithelial cells has been documented in several tissues including the lung; however, the majority of research has focused on the skin and specifically psoriasis. [6] Psoriasis is an immune-mediated inflammatory disease affecting 2% of the world population. [13] Psoriasis pathology is associated with hyperkeratotic plaques and epidermal inflammatory cell infiltrates.
This leads to visible raised erythematous scaly lesions. T-cells and the adaptive immune system are key players in psoriasis. However, innate inflammatory mediators such as IL-1 family members, IL-23, IL-10 family members, CCL20, IL-8, TNFα and antimicrobial peptides are now well recognised for their role in both the initiation and maintenance of psoriatic inflammation. [14, 15] *Authors contributed equally IL-36γ is highly upregulated in psoriasis lesions on both the mRNA and protein levels. [16] Expression levels of IL-36γ also correlate with levels of other cytokines such as IL-17, IL-23 and TNFα in psoriasis lesions. [5] Transgenic mice in which keratinocytes overexpress IL-36α are susceptible to a psoriasis-like inflammation following 12-O-tetra decanoylphorbol-13-acetate treatment. [17] Using the same model, mice which were deficient in the IL-36Ra showed chronic skin abnormalities and enhanced plaque development. Mice deficient in the IL-36R were protected from plaque development. [18] Also of note, generalised pustular psoriasis (GPP), a severe form of psoriasis, has been linked to loss-offunction mutations in the IL-36Ra. These mutations result in a less stable protein with resultant reduced control over IL-36-mediated responses. [19] The pathophysiologic contribution of endothelial cells (ECs) in psoriatic inflammation is well recognised. Psoriasis lesions show a developed vascular network, most notably in the papillary dermis. Studies have confirmed these capillaries are wide, dilated, tortuous and leaky. [20] [21] [22] The combination of endothelial activation followed by angiogenesis leads to enhanced and sustained leucocyte recruitment/migration to the lesion and thus tissue inflammation. [23, 24] Upregulation of adhesion molecules such as VCAM-1 (vascular cell adhesion molecule 1) and ICAM-1 (intercellular adhesion molecule 1) has been detected, which increases adhesion of leucocytes and leads to extravasation. [25] Several currently used medications for psoriasis may also work by affecting ECs along with immune cells. Methotrexate is thought to inhibit adhesion molecule expression. [26] Moreover, Efalizumab, which was efficient for psoriasis treatment when available, works by blocking LFA-1 (lymphocyte function-associated antigen 1) on leucocytes so they are unable to bind to the adhesion molecule ICAM-1 on ECs. [27] A number of proinflammatory cytokines upregulated in psoriatic lesions including TNFα and IL-17 are capable of activating ECs. [23, 28] The purpose of this study was to determine the effect of IL-36γ on ECs.
| METHODS

| Generation of IL-36 proteins
As IL-36 and IL-36Ra both require N-terminal processing to become fully active, [3] recombinant active forms of IL-36γ (IL-36γS18) and IL-36Ra (IL-36 RaV2) were used throughout. Constructs of IL-36γ S18 and IL-36 RaV2 containing N-terminal His-SUMO fusion partners were generated and expressed in BL21 (DE3) Codon + E. coli as described before. [29] Proteins were subsequently purified using Ni
2+
-affinity and size exclusion chromatography. Once purified, the SUMO tag was removed using the Ulp1 protease, and the final active recombinant cytokines were purified by Ni 2+ -affinity, ion exchange and size exclusion chromatography.
| Cell culture and stimulations
Umbilical cords were supplied by Bradford Royal Infirmary under the approval and processing of Ethical Tissue Bradford. HUVECs (human umbilical vein endothelial cells) from five donors were isolated from umbilical cords in a previously described method. [30] HDLECs (human dermal lymphatic endothelial cells) from pooled donors were supplied from PromoCell (Heidelberg, Germany The specificity of IMD-0354 at the doses used as previously been documented.
[31]
| IL-36 receptor confirmation by quantitative PCR (qPCR)
Cells were washed with PBS, and RNA was isolated using Quick-RNA MiniPrep (Zymo Research, Irvine, USA) according to the manufacturer's instructions. RNA was converted to cDNA using RevertAid first strand cDNA synthesis kit (Thermo Scientific, Waltham, USA), according to the manufacturer's instructions. cDNA from previously isolated and cultured human primary keratinocytes and fibroblasts were used as positive controls. [32] Quantitative PCR (qPCR) was performed using the QuantiFast SYBR Green PCR Kit (Qiagen). Primers for the IL-36R
(IL1RL2) were purchased from Qiagen. Data were analysed using BIO-RAD CFX ™ manager software version 3.0. Results were normalised against the housekeeping gene U6snRNA. The average values for the different cell types were then expressed as a ratio of the keratinocyte value (1.00). 
| IL-36 receptor confirmation by immunocytochemistry (ICC)
HUVEC
| NF-κB and c-JUN analysis by Western blot
Cells were stimulated as before, for 1 hour. Cells were lysed with 
| NF-κB and c-JUN activity by immunocytochemistry
Gelatin-coated coverslips were placed into six-well plates, and HUVEC were cultured and stimulated as before. Following 1 hour of treatment, cells were washed in TBS and fixed in 4% formaldehyde for 20 minutes. Cells were then blocked for 1 hour in 5% BSA in TBS.
Cells were then incubated overnight at 4°C with either rabbit antihuman phospho-NF-κB (1:1000) or rabbit anti-human phospho-c-JUN
(1:1000) (both Cell Signalling Technology, Leiden, the Netherlands).
Cells were washed with TBST, and a secondary donkey anti-rabbit 
| Chemokine analysis by ELISA
Following stimulation, CCL2 and IL-8 concentrations were measured using ELISA kits from eBioscience (San Diego, USA). CCL20
was measured using R&D systems kit (Minneapolis, USA). ELISAs were carried out according to the manufacturer's protocols.
Reproducibility of supernatants were confirmed by triplicate testing, with <10% error.
| Endothelial cell adhesion molecule analysis by flow cytometry
Following stimulation, cells were scraped in PBS. 
| Chemotaxis assay
Chemotaxis plates (101-216, 8 μm pore size) were purchased from Neuro Probe, USA. Thirty microlitres of supernatant was placed in the bottom chamber. The porous insert was then placed on top. 
| Statistical analysis
Statistical significance was calculated using a one-way ANOVA with
Bonferroni's multiple comparisons test, unless stated. Analysis was performed using GraphPad Prism software (GraphPad Software Inc, La Jolla, CA, USA). Error bars represent the standard error of the mean (SEM). *: P<.05 from indicated controls.
| RESULTS
| The IL-36R is present on endothelial cells
As show no expression. [10] qPCR analysis confirmed expression of the IL-36R by both HUVEC and HDLEC ( Figure 1A ). ICC confirmed the expression at protein level on both HUVEC and HDLEC ( Figure 1B ). Statistical analysis performed showed the MFI for untreated controls was statistically significant when compared to IL-36 50 ng/mL MFI, for both cell types and adhesion molecules.
| IL-36γ activates NF-κB and c-JUN
| Endothelial cells secrete chemokines following IL-36 stimulation
To assess the functional significance of IL-36R receptor expression on 
| Supernatant from IL-36γ-stimulated ECs is a chemoattractant for T-cells
Having observed chemokine secretion by ECs following IL-36γ stimulation, the chemotactic potency of the EC conditioned media was assessed. CCL20, which we found to be secreted by ECs following IL-36γ stimulation, is known to be a chemoattractant for lymphocytes and has a documented role in psoriasis. [33] Untreated cell supernatant, media alone and IL-36γ + media were used as negative controls and rhCCL20 as a positive control. Supernatant from IL-36γ-stimulated ECs proved to be a chemoattractant for T-cells when compared to negative controls ( Figure 4D) . A dose dependency for the IL-36γ effect on endothelial cells' capacity to increase T-cell migration was seen. Chemotaxis assays could confirm that IL-36Ra at 100 ng/mL was sufficient to inhibit the effects of IL-36γ 10 ng/mL. When stimulating with the Ra at 100 ng/mL, the migration of T-cells was reduced and comparable to untreated supernatant. This suggests IL-36γ-induced chemokine secretion was indeed responsible for T-cell migration.
| DISCUSSION
Psoriasis is a common chronic inflammatory skin disorder affecting around 2% of the population. The IL-1 family member, IL-36, has been linked to psoriasis pathogenesis and disease severity. In psoriasis and other inflammatory diseases, ECs are activated by proinflammatory cytokines, resulting in enhanced leucocyte recruitment. However, so far the effect of IL-36 on ECs has been unexplored.
Here, we describe that the IL-36 receptor is expressed by both HUVEC and HDLEC. We assessed the functional activity of the receptor by assessing the biologic response of ECs to IL-36γ stimulation, including adhesion molecule upregulation and chemokine production. and VCAM-1, respectively. [34] In the context of psoriasis pathogenesis, both these adhesion molecules are required for T-cell adhesion and migration into the skin. [17, 35] IL-36 stimulation and subsequent chemokine secretion have been shown to be dependent on the activation of transcription factors AP-1
and NF-κB. [36] We report activation of both these transcription factors in ECs (Figure 2 ). ECs responded with chemokine production to IL-36γ stimulation. CCL2 (MCP-1) has a documented importance in psoriasis and other inflammatory diseases by recruiting monocytes. [37] IL-8, which promotes neutrophil recruitment, EC survival and angiogenesis, was also secreted following IL-36γ stimulation. [38] The importance of angiogenesis in psoriasis is well recognised, [39] and local EC secretion of IL-8 induced by IL-36γ could be a contributing factor. CCL20 was secreted, which binds to CCR6, which is highly expressed on IL-17 and IL-22 producing lymphocytes, and the majority of T-cells that infiltrate the skin in psoriasis are CCR6 positive. [33] Chemotaxis assays confirmed increased T-cell migration following IL-36γ EC stimulation, which could be due to CCL20
secretion. Although keratinocytes are a main source of CCL20, [33, 40] our findings indicate that ECs can contribute to the cutaneous CCL20 as well as CCL2 production. For all chemokines analysed, the IL-36Ra was able to dampen the effect in a dose-dependent manner. This finding was also mirrored in the chemotaxis assay where T-cell migration was reduced when cells had been co-stimulated with the Ra.
It is hypothesised that environmental triggers can cause keratinocytes to secrete IL-36γ independently of proinflammatory cytokines such as TNFα. [17, 35] It is thus possible that IL-36γ could be important in the initiation of EC activation.
Our findings presented here could also have implications for other diseases. Lung bronchial epithelial cells secrete IL-36γ in response to cytokines such as TNFα. [6] Cigarette smoke, the causative agent of chronic obstructive pulmonary disease (COPD), is also known to cause IL-36γ secretion in bronchial epithelial cells. [7] However, the exact role of IL-36 in respiratory disease is still unknown. IL-36α has been shown to be expressed in the synovium of both psoriatic and rheumatoid arthritis patients, [41] whilst both α and y have been implicated in Crohn's disease in mouse models. [42] In COPD, Crohn's disease and rheumatoid arthritis, like many chronic inflammatory diseases, angiogenesis and EC activation occurs. [43] [44] [45] Therefore, IL-36 may also have a role in EC activation and leucocyte recruitment in these diseases. Murine models of liver damage/liver inflammation have also identified enhanced expression of IL-36γ and elevated CCL20 levels. [46] EC-induced secretion of CCL20 by IL-36γ could be one of the potential sources of this.
IL-36γ serum levels are enhanced in psoriasis patients. [16] In recent years, psoriasis has been suggested as an independent risk factor for atherosclerosis. [47, 48] In atherosclerosis, endothelium activation and initial inflammatory signalling represent an important stage of disease development. [49] Increased serum levels of IL-36γ and therefore possible increased endothelium activation of the arteries could accelerate atherosclerosis disease progression. Of note, generalised pustular psoriasis (GPP) can be associated with loss-of-function mutations in IL-36Ra and results in reduced control over IL-36. However, the risk factor of GPP on cardiovascular disease is largely unexplored. 
